TNG-260

N/A

Report date: 2024/03/07 17:49:27
NME

Base Information

Drug NameTNG-260
Drug Alias NameTNG-260
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase 1 inhibitorsLysine-specific histone demethylase 1 inhibitorsREST corepressor 1 inhibitors
TargetsHistone deacetylase 1Lysine-specific histone demethylase 1REST corepressor 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTango Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTango Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A